Terns Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Terns Pharmaceuticals

15/05/2023 14:37

* Terns Pharmaceuticals Inc  TERN.OQ  reported a quarterly
adjusted loss of 31 cents​​ per share for the quarter ended in
March. The mean expectation of seven analysts for the quarter
was for a loss of 27 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Terns Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 31 cents​.
    * The mean earnings estimate of analysts had risen by
about 35% in
the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Terns Pharmaceuticals Inc shares had risen by 6.9% this
quarter and gained 24.4% so far this year.
    * The company reported a quarterly loss of $21.53 million.
    * Wall Street's median 12-month price target for Terns
Pharmaceuticals Inc is $17.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 01:37 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.27          -0.31          Missed
 Dec. 31 2022      -0.43          -0.29          Beat
 Sep. 30 2022      -0.52          -0.44          Beat
 Jun. 30 2022      -0.59          -0.55          Beat